-
Something wrong with this record ?
Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
RČ. Pařízková, J. Martínková, E. Havel, P. Šafránek, M. Kaška, D. Astapenko, J. Bezouška, J. Chládek, V. Černý
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
PROGRES Q40/04
Ministerstvo Školství, Mládeže a Tělovýchovy
NT14089-3/2013
Ministerstvo Zdravotnictví Ceské Republiky
15-31881A
Ministerstvo Zdravotnictví Ceské Republiky
NLK
BioMedCentral
from 1997-04-01
BioMedCentral Open Access
from 1997
Directory of Open Access Journals
from 1998
Free Medical Journals
from 1997
PubMed Central
from 1997
Europe PubMed Central
from 1997
ProQuest Central
from 2015-01-01
Open Access Digital Library
from 1997-08-01
Open Access Digital Library
from 1997-01-01
Open Access Digital Library
from 1998-01-01
Medline Complete (EBSCOhost)
from 2011-02-01
Health & Medicine (ProQuest)
from 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1997
Springer Nature OA/Free Journals
from 1997-04-01
- MeSH
- Anti-Bacterial Agents metabolism pharmacokinetics MeSH
- APACHE MeSH
- Bayes Theorem MeSH
- Adult MeSH
- Pharmacokinetics * MeSH
- Intensive Care Units organization & administration statistics & numerical data MeSH
- Critical Illness therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Meropenem metabolism pharmacokinetics MeSH
- Prospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sepsis drug therapy physiopathology MeSH
- Water-Electrolyte Balance drug effects MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
BACKGROUND: Meropenem dosing for septic critically patients is difficult due to pathophysiological changes associated with sepsis as well as supportive symptomatic therapies. A prospective single-center study assessed whether fluid retention alters meropenem pharmacokinetics and the achievement of the pharmacokinetic/pharmacodynamic (PK/PD) targets for efficacy. METHODS: Twenty-five septic ICU patients (19 m, 6f) aged 32-86 years with the mean APACHE II score of 20.2 (range 11-33), suffering mainly from perioperative intra-abdominal or respiratory infections and septic shock (n = 18), were investigated over three days after the start of extended 3-h i.v. infusions of meropenem q8h. Urinary creatinine clearance (CLcr) and cumulative fluid balance (CFB) were measured daily. Plasma meropenem was measured, and Bayesian estimates of PK parameters were calculated. RESULTS: Eleven patients (9 with peritonitis) were classified as fluid overload (FO) based on a positive day 1 CFB of more than 10% body weight. Compared to NoFO patients (n = 14, 11 with pneumonia), the FO patients had a lower meropenem clearance (CLme 8.5 ± 3.2 vs 11.5 ± 3.5 L/h), higher volume of distribution (V1 14.9 ± 3.5 vs 13.5 ± 4.1 L) and longer half-life (t1/2 1.4 ± 0.63 vs 0.92 ± 0.54 h) (p < 0.05). Over three days, the CFB of the FO patients decreased (11.7 ± 3.3 vs 6.7 ± 4.3 L, p < 0.05) and the PK parameters reached the values comparable with NoFO patients (CLme 12.4 ± 3.8 vs 11.5 ± 2.0 L/h, V1 13.7 ± 2.0 vs 14.0 ± 5.1 L, t1/2 0.81 ± 0.23 vs 0.87 ± 0.40 h). The CLcr and Cockroft-Gault CLcr were stable in time and comparable. The correlation with CLme was weak to moderate (CLcr, day 3 CGCLcr) or absent (day 1 and 2 CGCLcr). Dosing with 2 g meropenem q8h ensured adequate concentrations to treat infections with sensitive pathogens (MIC 2 mg/L). The proportion of pre-dose concentrations exceeding the MIC 8 mg/L and the fraction time with a target-exceeding concentration were higher in the FO group (day 1-3 f Cmin > MIC: 67 vs 27%, p < 0.001; day 1%f T > MIC: 79 ± 17 vs 58 ± 17, p < 0.05). CONCLUSIONS: These findings emphasize the importance of TDM and a cautious approach to augmented maintenance dosing of meropenem to patients with FO infected with less susceptible pathogens, if guided by population covariate relationships between CLme and creatinine clearance.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004079
- 003
- CZ-PrNML
- 005
- 20220127145600.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13054-021-03680-9 $2 doi
- 035 __
- $a (PubMed)34274013
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Pařízková, Renata Černá $u Department of Anesthesiology, Resuscitation and Intensive Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 245 10
- $a Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis / $c RČ. Pařízková, J. Martínková, E. Havel, P. Šafránek, M. Kaška, D. Astapenko, J. Bezouška, J. Chládek, V. Černý
- 520 9_
- $a BACKGROUND: Meropenem dosing for septic critically patients is difficult due to pathophysiological changes associated with sepsis as well as supportive symptomatic therapies. A prospective single-center study assessed whether fluid retention alters meropenem pharmacokinetics and the achievement of the pharmacokinetic/pharmacodynamic (PK/PD) targets for efficacy. METHODS: Twenty-five septic ICU patients (19 m, 6f) aged 32-86 years with the mean APACHE II score of 20.2 (range 11-33), suffering mainly from perioperative intra-abdominal or respiratory infections and septic shock (n = 18), were investigated over three days after the start of extended 3-h i.v. infusions of meropenem q8h. Urinary creatinine clearance (CLcr) and cumulative fluid balance (CFB) were measured daily. Plasma meropenem was measured, and Bayesian estimates of PK parameters were calculated. RESULTS: Eleven patients (9 with peritonitis) were classified as fluid overload (FO) based on a positive day 1 CFB of more than 10% body weight. Compared to NoFO patients (n = 14, 11 with pneumonia), the FO patients had a lower meropenem clearance (CLme 8.5 ± 3.2 vs 11.5 ± 3.5 L/h), higher volume of distribution (V1 14.9 ± 3.5 vs 13.5 ± 4.1 L) and longer half-life (t1/2 1.4 ± 0.63 vs 0.92 ± 0.54 h) (p < 0.05). Over three days, the CFB of the FO patients decreased (11.7 ± 3.3 vs 6.7 ± 4.3 L, p < 0.05) and the PK parameters reached the values comparable with NoFO patients (CLme 12.4 ± 3.8 vs 11.5 ± 2.0 L/h, V1 13.7 ± 2.0 vs 14.0 ± 5.1 L, t1/2 0.81 ± 0.23 vs 0.87 ± 0.40 h). The CLcr and Cockroft-Gault CLcr were stable in time and comparable. The correlation with CLme was weak to moderate (CLcr, day 3 CGCLcr) or absent (day 1 and 2 CGCLcr). Dosing with 2 g meropenem q8h ensured adequate concentrations to treat infections with sensitive pathogens (MIC 2 mg/L). The proportion of pre-dose concentrations exceeding the MIC 8 mg/L and the fraction time with a target-exceeding concentration were higher in the FO group (day 1-3 f Cmin > MIC: 67 vs 27%, p < 0.001; day 1%f T > MIC: 79 ± 17 vs 58 ± 17, p < 0.05). CONCLUSIONS: These findings emphasize the importance of TDM and a cautious approach to augmented maintenance dosing of meropenem to patients with FO infected with less susceptible pathogens, if guided by population covariate relationships between CLme and creatinine clearance.
- 650 _2
- $a APACHE $7 D018806
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a antibakteriální látky $x metabolismus $x farmakokinetika $7 D000900
- 650 _2
- $a Bayesova věta $7 D001499
- 650 _2
- $a kritický stav $x terapie $7 D016638
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jednotky intenzivní péče $x organizace a řízení $x statistika a číselné údaje $7 D007362
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a meropenem $x metabolismus $x farmakokinetika $7 D000077731
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a farmakokinetika $7 D010599
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a sepse $x farmakoterapie $x patofyziologie $7 D018805
- 650 _2
- $a vodní a elektrolytová rovnováha $x účinky léků $7 D014882
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Martínková, Jiřina $u Department of Surgery, University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Havel, Eduard $u Department of Surgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Šafránek, Petr $u Department of Surgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Kaška, Milan $u Department of Surgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Astapenko, David $u Department of Anesthesiology, Resuscitation and Intensive Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Bezouška, Jan $u Department of Surgery, University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 700 1_
- $a Chládek, Jaroslav $u Department of Pharmacology, Charles University, Faculty of Medicine in Hradec Králové, Šimkova 870, 50003, Hradec Králové, Czech Republic. chladekj@lfhk.cuni.cz
- 700 1_
- $a Černý, Vladimír $u Department of Anesthesiology, Resuscitation and Intensive Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
- 773 0_
- $w MED00006603 $t Critical care (London, England) $x 1466-609X $g Roč. 25, č. 1 (2021), s. 251
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34274013 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145556 $b ABA008
- 999 __
- $a ok $b bmc $g 1751515 $s 1155228
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 25 $c 1 $d 251 $e 20210717 $i 1466-609X $m Critical care $n Crit Care $x MED00006603
- GRA __
- $a PROGRES Q40/04 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a NT14089-3/2013 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a 15-31881A $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20220113